Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04976296

MRD Monitoring in Lung Cancer After Resection

Dynamic Molecular Residual Disease Detection in Stage I-IIIA Non-Small Cell Lung Cancer After Radical Resection

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Guangdong Provincial People's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The conception of molecular residual disease (MRD) extending from hematologic tumor to solid tumors. Evidences supporting MRD evaluation for lung cancer by liquid biopsy has gradually accumulated, especially circulating tumor DNA (ctDNA). In this observational study, the investigators prospectively enroll stage I-IIIA non-small cell lung cancer (NSCLC) patients who underwent complete resection. Preoperative blood sample, tumor tissue and dynamic postoperative blood samples are collected continuously for MRD detection. This study aim to explore the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.

Detailed description

There will be a rapid surge in research about molecular residual disease (MRD) for solid cancer in the near future. However, MRD differed significantly between tumor types and between contexts; there continues to be a considerable lack of awareness and knowledge about using MRD in lung cancer. Hence, this study aims to investigate the value of MRD in NSCLC patients who underwent complete resection. Preoperative blood sample (20ml), tumor tissue and dynamic postoperative blood samples (20ml) are collected continuously for MRD detection. The follow-up was performed once every 3 to 6 months. The primary objective of this study is to assess the prognostic value of MRD for stage I-IIIA NSCLC patients after complete resection.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTMRD detectionThe Geneplus OncoMRD lung assay is used to detect the MRD status.

Timeline

Start date
2021-09-01
Primary completion
2027-12-30
Completion
2027-12-30
First posted
2021-07-26
Last updated
2022-03-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04976296. Inclusion in this directory is not an endorsement.

MRD Monitoring in Lung Cancer After Resection (NCT04976296) · Clinical Trials Directory